Why do orally-administered drugs for diabetes work for some people but not others? According to researchers bacteria that make up the gut microbiome may be the culprit.
In a review of more than 100 current published studies in humans and rodents, the team examined how gut bacteria either enhanced or inhibited a drug's effectiveness. The review is published in the journal EBioMedicine.
"For example, certain drugs work fine when given intravenously and go directly to the circulation, but when they are taken orally and pass through the gut, they don't work," said the senior author.
"Conversely, metformin, a commonly used anti-diabetes drug, works best when given orally but does not work when given through an IV."
The review examined interactions between the most commonly prescribed anti-diabetic drugs with the microbiome. Before being absorbed into the bloodstream, many orally-administered drugs are processed by intestinal microbial enzymes. As a result, the gut microbiome influences the metabolism of the drugs, thereby affecting patients' responses, the senior author said.
Type-2 diabetes, a disease characterized by carbohydrate and fat metabolism abnormalities, has recently become a global pandemic. One main function of gut microbiota is to metabolize non-digestive carbohydrates and regulate a person's metabolism.
"Our review showed that the metabolic capacity of a patient's microbiome could influence the absorption and function of these drugs by making them pharmacologically active, inactive or even toxic," the author aid. "We believe that differences in an individual's microbiome help explain why drugs will show a 90 or 50 percent optimum efficacy, but never 100 percent."
The researchers concluded that modulation of the gut microbiome by drugs may represent a target to improve, modify or reverse the effectiveness of current medications for type-2 diabetes.
"This field is only a decade old, and the possibility of developing treatments derived from bacteria related to or involved in specific diseases is tantalizing," the senior author said.
https://www.eurekalert.org/pub_releases/2018-12/wfbm-gmm121118.php
https://www.ebiomedicine.com/article/S2352-3964(18)30550-4/fulltext
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fbi-directional-drug&filter=22
Latest News
SNUPN gene responsible for…
By newseditor
Posted 03 May
A brain circuit inhibits fo…
By newseditor
Posted 03 May
A hydrogel therapy defends…
By newseditor
Posted 03 May
Role of lipid droplets in A…
By newseditor
Posted 03 May
AI designs new drugs based…
By newseditor
Posted 03 May
Other Top Stories
Complex gene mutations seen in chromosome 17
Read more
Mutation in glycosyltransferase implicated in ALS
Read more
Gene therapy restores vision in blind mice
Read more
A master regulator of regeneration identified!
Read more
Serotonylation of histones to regulate gene expression
Read more
Protocols
Generation of rat forebrain…
By newseditor
Posted 03 May
Ultrasound-visible engineer…
By newseditor
Posted 03 May
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Publications
SNUPN deficiency causes a r…
By newseditor
Posted 03 May
Nausea-induced suppression…
By newseditor
Posted 03 May
Antiviral fibrils of self-a…
By newseditor
Posted 03 May
Educate, not kill: treating…
By newseditor
Posted 03 May
Structure of the interleuki…
By newseditor
Posted 03 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar